Andrea Murino, a partner and co-chair of Goodwin’s Antitrust & Competition Law Practice, examines the latest on the Aetna Inc., Humana Inc. $33 billion purchase and why the U.S. government’s legal battle to try to reinstate the deal may fail.
The full Reuters article here.
Related Content
- Goodwin InsightsFebruary 21, 2023
Antitrust & Competition Healthcare Quarterly Update Q4 2022
- Goodwin InsightsFebruary 21, 2023
Antitrust & Competition Technology 2022 Year in Review
- Goodwin InsightsFebruary 21, 2023
Antitrust & Competition Life Sciences 2022 Year In Review
- Goodwin InsightsFebruary 3, 2023
Regulators Align in Their Focus on Digital Advertising
- AlertJanuary 24, 2023
2023 HSR Thresholds Announced: $111.4 million
- AlertNovember 11, 2022
Federal Trade Commission Issues Expansive New Policy Statement Regarding Enforcement Powers Under Section 5 of the FTC Act
- AlertOctober 11, 2022
DOJ Intensifies Investigations Into Overlapping Board Membership and Senior Officers Between Competitors
- AlertSeptember 22, 2022
DOJ Cracking Down on Private Equity Interlocking Directorates Between Competing Portfolio Companies
- Press ReleaseMarch 23, 2023
Moderna and Generation Bio Announce $76 Million Strategic Collaboration to Develop Non-Viral Genetic Medicines
- In the PressMarch 22, 2023
Goodwin Snags Tech and Life Sciences Litigation Trio (Commercial Dispute Resolution)
- In the PressMarch 22, 2023
Goodwin Adds 3 IP Litigators In NY (Law360)
- In the PressMarch 22, 2023
Goodwin Grows New York IP Litigation Practice by Three Partners (Bloomberg Law)
- Press ReleaseMarch 21, 2023
Goodwin Welcomes Leading Technology and Life Sciences Litigation Team in New York
- Press ReleaseMarch 16, 2023
Storage Solutions Acquired by Jungheinrich
- Press ReleaseMarch 13, 2023
Qualtrics To Become a Private Company Through $12.5 Billion Acquisition by Silver Lake and CPP Investments
- Awards and RankingsFebruary 23, 2023
Goodwin Named an Elite Firm for Antitrust Law by GCR 100 2023